Category: Latest News

  • MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX)

    MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX)

    MBX Biosciences Inc. (NASDAQ:MBX) shares dropped 19.6% in premarket trading on Friday despite the company reporting encouraging one-year clinical data for its investigational treatment canvuparatide in patients with chronic hypoparathyroidism. The clinical-stage biopharmaceutical company released updated findings from its 12-week Avail Phase 2 study alongside one-year results from an ongoing open-label extension trial evaluating once-weekly…

  • Momentus Shares Slide After Announcing $25 Million Equity Offering (MNTS)

    Momentus Shares Slide After Announcing $25 Million Equity Offering (MNTS)

    Momentus Inc. (NASDAQ:MNTS) shares fell 18% in premarket trading on Friday after the commercial space company unveiled plans to raise $25 million through a stock offering aimed at institutional investors. The transaction is expected to provide additional capital for the company’s operations, although the prospect of shareholder dilution weighed on investor sentiment. Company Launches Registered…

  • Rezolve AI Shares Climb After Board Proposes $300 Million Buyback Programme (RZLV)

    Rezolve AI Shares Climb After Board Proposes $300 Million Buyback Programme (RZLV)

    Rezolve AI Ltd (NASDAQ:RZLV) shares rose 7.1% in premarket trading on Friday after the company announced plans to seek shareholder approval for a proposed share repurchase programme worth up to $300 million. The initiative is intended to allow the company to buy back a substantial amount of its outstanding stock, reflecting management’s confidence in the…

  • HUTCHMED Shares Rise After Positive Phase III Results Presented at EHA Congress (HCM)

    HUTCHMED Shares Rise After Positive Phase III Results Presented at EHA Congress (HCM)

    HUTCHMED (NASDAQ:HCM) shares gained 2.4% in premarket trading on Friday after the company unveiled encouraging Phase III clinical trial results for sovleplenib in patients with warm antibody autoimmune hemolytic anemia (wAIHA) at the European Hematology Association (EHA) Congress. The findings were presented on Thursday at the EHA meeting in Stockholm, Sweden, and were selected for…

  • Richtech Robotics Shares Slide After Financial Restatement Announcement (RR)

    Richtech Robotics Shares Slide After Financial Restatement Announcement (RR)

    Richtech Robotics Inc (NASDAQ:RR) shares dropped 12% in premarket trading on Friday after the company revealed plans to restate financial statements covering multiple reporting periods following the identification of accounting errors. The Nevada-based robotics developer disclosed that its Audit Committee determined on June 9, 2026, that previously issued financial statements should no longer be relied…

  • Adobe Beats Expectations and Raises Outlook, but Shares Fall on ARR Concerns (ADBE)

    Adobe Beats Expectations and Raises Outlook, but Shares Fall on ARR Concerns (ADBE)

    Adobe (NASDAQ:ADBE) delivered stronger-than-expected second-quarter results on Thursday, surpassing Wall Street forecasts for both revenue and earnings while increasing its full-year guidance. However, the stock moved lower in premarket trading after investors focused on unchanged annual recurring revenue projections and another senior leadership transition. Shares of Adobe fell around 5% before the market open on…

  • Lennar Misses Earnings Expectations as Housing Market Challenges Continue (LEN)

    Lennar Misses Earnings Expectations as Housing Market Challenges Continue (LEN)

    Lennar Corporation (NYSE:LEN) reported second-quarter results that came in below market forecasts, as the homebuilder continued to contend with affordability pressures, elevated mortgage rates and cautious buyer sentiment across the U.S. housing market. For the quarter ended 31 May 2026, Lennar generated adjusted earnings of $1.31 per share, excluding mark-to-market losses related to technology investments.…

  • Space Stocks Rally After SpaceX Sets Record IPO Price at $135 Per Share

    Space Stocks Rally After SpaceX Sets Record IPO Price at $135 Per Share

    SpaceX (NASDAQ:SPCX) confirmed on Thursday that it had priced its landmark initial public offering at $135 per share, raising $75 billion in what has become the largest IPO ever completed in the United States. The Elon Musk-led company sold 555.56 million shares, giving the rocket, satellite and spacecraft group an implied valuation of approximately $1.77…

  • SpaceX Faces Crucial Market Debut Following Historic IPO Success

    SpaceX Faces Crucial Market Debut Following Historic IPO Success

    SpaceX (NASDAQ:SPCX) is preparing to begin trading on Nasdaq on Friday after completing the largest initial public offering ever, with investors committing $75 billion in a vote of confidence that Elon Musk’s long-term ambitions in space exploration, communications and artificial intelligence can support a valuation of $1.77 trillion. The landmark flotation has cemented Musk’s position…

  • SpaceX Listing Pushes Elon Musk Beyond the Trillion-Dollar Mark

    SpaceX Listing Pushes Elon Musk Beyond the Trillion-Dollar Mark

    Elon Musk has become the world’s first trillionaire following the record-breaking initial public offering of SpaceX (NASDAQ:SPCX), further cementing his status as one of the most influential and closely watched business figures of the modern era. Few corporate leaders have achieved the level of public recognition enjoyed by Musk, whose blend of technological ambition, outspoken…